MX341174B - Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. - Google Patents

Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.

Info

Publication number
MX341174B
MX341174B MX2013002212A MX2013002212A MX341174B MX 341174 B MX341174 B MX 341174B MX 2013002212 A MX2013002212 A MX 2013002212A MX 2013002212 A MX2013002212 A MX 2013002212A MX 341174 B MX341174 B MX 341174B
Authority
MX
Mexico
Prior art keywords
treatment
heart failure
hypertension
prevention
receiving anti
Prior art date
Application number
MX2013002212A
Other languages
English (en)
Other versions
MX2013002212A (es
Inventor
Albrecht Diego
Chandra Priyamvada
Godtfredsen Sven
Jordaan Pierre
Lefkowitz Martin
Original Assignee
Novartis Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341174(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag * filed Critical Novartis Ag *
Publication of MX2013002212A publication Critical patent/MX2013002212A/es
Publication of MX341174B publication Critical patent/MX341174B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a métodos y composiciones farmacéuticas para el tratamiento de hipertensión y/o para prevenir o tratar insuficiencia cardíaca en un mamífero que reciba terapia anti-coagulante utilizando compuestos que sean terapéuticamente efectivos pero que no tengan un impacto sobre los efectos farmacocinéticos o farmacodinámicos del anti-coagulante, tal como warfarina.
MX2013002212A 2010-08-24 2011-08-22 Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. MX341174B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37641710P 2010-08-24 2010-08-24
PCT/US2011/048542 WO2012027237A1 (en) 2010-08-24 2011-08-22 Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy

Publications (2)

Publication Number Publication Date
MX2013002212A MX2013002212A (es) 2013-05-09
MX341174B true MX341174B (es) 2016-08-10

Family

ID=44543868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002212A MX341174B (es) 2010-08-24 2011-08-22 Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.

Country Status (17)

Country Link
US (2) US20130158088A1 (es)
EP (1) EP2608784B1 (es)
JP (1) JP2013536230A (es)
KR (1) KR101864865B1 (es)
CN (1) CN103079554A (es)
AU (1) AU2011293648B2 (es)
BR (1) BR112013004192A2 (es)
CA (1) CA2807830C (es)
CL (1) CL2013000513A1 (es)
ES (1) ES2702529T3 (es)
GT (1) GT201300047A (es)
MA (1) MA34483B1 (es)
MX (1) MX341174B (es)
RU (1) RU2564941C2 (es)
SG (1) SG187755A1 (es)
TW (1) TW201208678A (es)
WO (1) WO2012027237A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108685889A (zh) 2012-08-24 2018-10-23 诺华股份有限公司 用于治疗特征为心房增大或重构的疾病的nep抑制剂
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
ES2767084T3 (es) 2013-08-26 2020-06-16 Novartis Ag Nuevo uso
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN110922366B (zh) 2014-12-08 2023-02-03 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CA3010778C (en) 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
US20190307107A1 (en) * 2016-06-13 2019-10-10 The Board Of Regents Of The University Of Texas System Compositions and methods for modeling heart failure with preserved ejection fraction
CA3110152A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US6869357B2 (en) * 2001-12-19 2005-03-22 Igt Methods of conducting games of chance and gaming devices with multiple pay lines
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US7857515B2 (en) * 2007-06-15 2010-12-28 S.C. Johnson Home Storage, Inc. Airtight closure mechanism for a reclosable pouch
JP5653218B2 (ja) * 2007-11-06 2015-01-14 ノバルティス アーゲー アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物

Also Published As

Publication number Publication date
MA34483B1 (fr) 2013-08-01
EP2608784B1 (en) 2018-09-19
US20130158088A1 (en) 2013-06-20
CA2807830C (en) 2018-04-03
BR112013004192A2 (pt) 2016-05-10
GT201300047A (es) 2014-07-08
RU2564941C2 (ru) 2015-10-10
CN103079554A (zh) 2013-05-01
WO2012027237A1 (en) 2012-03-01
AU2011293648B2 (en) 2015-02-12
TW201208678A (en) 2012-03-01
US20140329872A1 (en) 2014-11-06
EP2608784A1 (en) 2013-07-03
MX2013002212A (es) 2013-05-09
JP2013536230A (ja) 2013-09-19
SG187755A1 (en) 2013-03-28
RU2013112859A (ru) 2014-09-27
CA2807830A1 (en) 2012-03-01
CL2013000513A1 (es) 2014-08-29
KR101864865B1 (ko) 2018-06-05
KR20130095754A (ko) 2013-08-28
ES2702529T3 (es) 2019-03-01
AU2011293648A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
MX2013002212A (es) Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante.
EP2477985A4 (en) CANCER TREATMENT
WO2012025213A3 (en) Novel therapeutic compounds
UA115983C2 (uk) Інгібітори днк-пк
MY178621A (en) Deuterated cftr potentiators
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
MX2012011380A (es) Compuestos aromaticos multisustituidos como inhibidores de trombina.
IN2012DN00971A (es)
PH12018501227A1 (en) Drug for preventing and/or treating polycystic kidney disease
MY165826A (en) Pharmaceutical composition
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
IN2012DN03807A (es)
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
GB2482817A (en) Novel use
CA2881554C (en) Methods for inhibiting fascin
WO2010032011A3 (en) Anti-fungal therapy
EA201200428A1 (ru) Композиция и способ для лечения ожирения
WO2009108755A3 (en) Pharmaceutical combinations for the treatment of cancer
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2010115741A3 (en) New therapeutic approaches for treating neuroinflammatory conditions

Legal Events

Date Code Title Description
FG Grant or registration